Virologica Sinica

, Volume 28, Issue 4, pp 193–201 | Cite as

Crimean-Congo hemorrhagic fever: An overview

Review

Abstract

Crimean-Congo hemorrhagic fever (CCHF) is a zoonotic viral infection that is a serious threat to humans. The disease is widely distributed in Africa, Asia, and Europe and has developed into a serious public health concern. Humans become infected through the bites of ticks, by contact with a patient with CCHF, or by contact with blood or tissues from viremic livestock. Microvascular instability and impaired hemostasis are the hallmarks of the infection. Infection in human begins with nonspecific febrile symptoms, but may progress to a serious hemorrhagic syndrome with high mortality rates. Enzyme-linked immunoassay (ELISA) and polymerase chain reaction (PCR) are the most used and specific tests for the diagnosis. The mainstay of treatment is supportive. Although definitive studies are not available, ribavirin is suggested to be effective especially at the earlier phase of the infection. Uses of universal protective measures are the best way to avoid the infection. In this review, all aspects of CCHF are overviewed in light of the current literature.

Keywords

Crimean-Congo Hemorrhagic Fever Epidemiology Transmission Pathogenesis Diagnosis Treatment Prevention 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anagnostou V, and Papa A. 2009. Evolution of Crimean-Congo Hemorrhagic Fever virus. Infect Genet Evol, 9: 948–954.PubMedCrossRefGoogle Scholar
  2. Appannanavar S B, and Mishra B. 2011. An update on crimean congo hemorrhagic Fever. J Glob Infect Dis, 3: 285–292.PubMedCrossRefGoogle Scholar
  3. Ascioglu S, Leblebicioglu H, Vahaboglu H, and Chan K A. 2011. Ribavirin for patients with Crimean-Congo haemorrhagic fever: a systematic review and meta-analysis. J Antimicrob Chemother, 66: 1215–1222.PubMedCrossRefGoogle Scholar
  4. Atkinson B, Chamberlain J, Logue C H, Cook N, Bruce C, Dowall S D, and Hewson R. 2012. Development of a real-time rt-PCR assay for the detection of crimean-congo hemorrhagic Fever virus. Vector Borne Zoonotic Dis, 12: 786–793.PubMedCrossRefGoogle Scholar
  5. Bajpai S, and Nadkar M Y. 2011. Crimean Congo hemorrhagic fever: requires vigilance and not panic. J Assoc Physicians India, 59: 164–167.PubMedGoogle Scholar
  6. Bakir M, Ugurlu M, Dokuzoguz B, Bodur H, Tasyaran M A, and Vahaboglu H. 2005. Crimean-Congo haemorrhagic fever outbreak in Middle Anatolia: a multicentre study of clinical features and outcome measures. J Med Microbiol, 54: 385–389.PubMedCrossRefGoogle Scholar
  7. Bakir M, Engin A, Gozel M G, Elaldi N, Kilickap S, and Cinar Z. 2012. A new perspective to determine the severity of cases with Crimean-Congo hemorrhagic fever. J Vector Borne Dis, 49: 105–110.PubMedGoogle Scholar
  8. Bangash S A, and Khan E A. 2003. Treatment and prophylaxis with ribavirin for Crimean-Congo Hemorrhagic Fever—is it effective? J Pak Med Assoc, 53: 39–41.PubMedGoogle Scholar
  9. Bente D A, Alimonti J B, Shieh W J, Camus G, Stroher U, Zaki S, and Jones S M. 2010. Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model. J Virol, 84: 11089–11100.PubMedCrossRefGoogle Scholar
  10. Bodur H, Akinci E, Ascioglu S, Onguru P, and Uyar Y. 2012. Subclinical infections with Crimean-Congo hemorrhagic fever virus, Turkey. Emerg Infect Dis, 18: 640–642.PubMedCrossRefGoogle Scholar
  11. Bodur H, Akinci E, Onguru P, Uyar Y, Basturk B, Gozel M G, and Kayaaslan B U. 2010. Evidence of vascular endothelial damage in Crimean-Congo hemorrhagic fever. Int J Infect Dis, 14: e704–707.PubMedCrossRefGoogle Scholar
  12. Bodur H, Erbay A, Akinci E, Onguru P, Bayazit N, Eren S S, and Kubar A. 2011. Effect of oral ribavirin treatment on the viral load and disease progression in Crimean-Congo hemorrhagic fever. Int J Infect Dis, 15: e44–47.PubMedCrossRefGoogle Scholar
  13. Burt F J, Leman P A, Abbott J C, and Swanepoel R. 1994. Serodiagnosis of Crimean-Congo haemorrhagic fever. Epidemiol Infect, 113: 551–562.PubMedCrossRefGoogle Scholar
  14. Cevik M A, Erbay A, Bodur H, Eren S S, Akinci E, Sener K, Onguru P, and Kubar A. 2007. Viral load as a predictor of outcome in Crimean-Congo hemorrhagic fever. Clin Infect Dis, 45: e96–100.PubMedCrossRefGoogle Scholar
  15. Cherenov I V, Galimzianov K M, Sologub T V, Romantsov M G, Lokteva O M, and Kovalenko A L. 2012. Efficacy of antiviral agents in the treatment of Crimean hemorrhagic fever. Klin Med (Mosk), 90: 59–62.Google Scholar
  16. Chinikar S, Ghiasi S M, Hewson R, Moradi M, and Haeri A. 2010. Crimean-Congo hemorrhagic fever in Iran and neighboring countries. J Clin Virol, 47: 110–114.PubMedCrossRefGoogle Scholar
  17. Deyde V M, Khristova M L, Rollin P E, Ksiazek T G, and Nichol S T. 2006. Crimean-Congo hemorrhagic fever virus genomics and global diversity. J Virol, 80: 8834–8842.PubMedCrossRefGoogle Scholar
  18. Drosten C, Gottig S, Schilling S, Asper M, Panning M, Schmitz H, and Gunther S. 2002. Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. J Clin Microbiol, 40: 2323–2330.PubMedCrossRefGoogle Scholar
  19. Duh D, Nichol S T, Khristova M L, Saksida A, Hafner-Bratkovic I, Petrovec M, Dedushaj I, Ahmeti S, and Avsic-Zupanc T. 2008. The complete genome sequence of a Crimean-Congo hemorrhagic fever virus isolated from an endemic region in Kosovo. Virol J, 5: 7.PubMedCrossRefGoogle Scholar
  20. Duygu F, Kaya T, and Baysan P. 2012. Re-evaluation of 400 crimean-congo hemorrhagic Fever cases in an endemic area: is ribavirin treatment suitable? Vector Borne Zoonotic Dis, 12: 812–816.PubMedCrossRefGoogle Scholar
  21. Elaldi N, Bodur H, Ascioglu S, Celikbas A, Ozkurt Z, Vahaboglu H, Leblebicioglu H, Yilmaz N, Engin A, Sencan M, Aydin K, Dokmetas I, Cevik M A, Dokuzoguz B, Tasyaran M A, Ozturk R, Bakir M, and Uzun R. 2009. Efficacy of oral ribavirin treatment in Crimean-Congo haemorrhagic fever: a quasi-experimental study from Turkey. J Infect, 58: 238–244.PubMedCrossRefGoogle Scholar
  22. Erduran E, and Cakir M. 2010. Reactive hemophagocytic lymphohistiocytosis and Crimean-Congo hemorrhagic fever. Int J Infect Dis, 14Suppl 3: e349; author reply e350.PubMedCrossRefGoogle Scholar
  23. Ergonul O. 2006. Crimean-Congo haemorrhagic fever. Lancet Infect Dis, 6: 203–214.PubMedCrossRefGoogle Scholar
  24. Ergonul O. 2008. Treatment of Crimean-Congo hemorrhagic fever. Antiviral Res, 78: 125–131.PubMedCrossRefGoogle Scholar
  25. Ergonul O. 2012. Crimean-Congo hemorrhagic fever virus: new outbreaks, new discoveries. Curr Opin Virol, 2: 215–220.PubMedCrossRefGoogle Scholar
  26. Ergonul O, Tuncbilek S, Baykam N, Celikbas A, and Dokuzoguz B. 2006. Evaluation of serum levels of interleukin (IL)-6, IL-10, and tumor necrosis factor-alpha in patients with Crimean-Congo hemorrhagic fever. J Infect Dis, 193: 941–944.PubMedCrossRefGoogle Scholar
  27. Ergonul O, Celikbas A, Dokuzoguz B, Eren S, Baykam N, and Esener H. 2004. Characteristics of patients with Crimean-Congo hemorrhagic fever in a recent outbreak in Turkey and impact of oral ribavirin therapy. Clin Infect Dis, 39: 284–287.PubMedCrossRefGoogle Scholar
  28. Ertugrul B, Kirdar S, Ersoy O S, Ture M, Erol N, Ozturk B, and Sakarya S. 2012. The seroprevalence of Crimean-Congo haemorrhagic fever among inhabitants living in the endemic regions of Western Anatolia. Scand J Infect Dis, 44: 276–281.PubMedCrossRefGoogle Scholar
  29. Ertugrul B, Uyar Y, Yavas K, Turan C, Oncu S, Saylak O, Carhan A, Ozturk B, Erol N, and Sakarya S. 2009. An outbreak of Crimean-Congo hemorrhagic fever in western Anatolia, Turkey. Int J Infect Dis, 13: e431–436.PubMedCrossRefGoogle Scholar
  30. Fisher-Hoch S P, Khan J A, Rehman S, Mirza S, Khurshid M, and McCormick J B. 1995. Crimean Congo-haemorrhagic fever treated with oral ribavirin. Lancet, 346: 472–475.PubMedCrossRefGoogle Scholar
  31. Geisbert T W, and Jahrling P B. 2004. Exotic emerging viral diseases: progress and challenges. Nat Med, 10: S110–121.PubMedCrossRefGoogle Scholar
  32. Hewson R, Chamberlain J, Mioulet V, Lloyd G, Jamil B, Hasan R, Gmyl A, Gmyl L, Smirnova S E, Lukashev A, Karganova G, and Clegg C. 2004. Crimean-Congo haemorrhagic fever virus: sequence analysis of the small RNA segments from a collection of viruses world wide. Virus Res, 102: 185–189.PubMedCrossRefGoogle Scholar
  33. Heyman P, Cochez C, Hofhuis A, van der Giessen J, Sprong H, Porter S R, Losson B, Saegerman C, Donoso-Mantke O, Niedrig M, and Papa A. 2010. A clear and present danger: tick-borne diseases in Europe. Expert Rev Anti Infect Ther, 8: 33–50.PubMedCrossRefGoogle Scholar
  34. Humolli I, Dedushaj I, Zupanac T A, and Mucaj S. 2010. Epidemiological, serological and herd immunity of Crimean-Congo haemorrhagic fever in Kosovo. Med Arh, 64: 91–93.PubMedGoogle Scholar
  35. Ibrahim S M, Aitichou M, Hardick J, Blow J, O’Guinn M L, and Schmaljohn C. 2011. Detection of Crimean-Congo hemorrhagic fever, Hanta, and sandfly fever viruses by real-time RT-PCR. Methods Mol Biol, 665: 357–368.PubMedCrossRefGoogle Scholar
  36. Izadi S, and Salehi M. 2009. Evaluation of the efficacy of ribavirin therapy on survival of Crimean-Congo hemorrhagic fever patients: a case-control study. Jpn J Infect Dis, 62: 11–15.PubMedGoogle Scholar
  37. Jameson L J, Morgan P J, Medlock J M, Watola G, and Vaux A G. 2012. Importation of Hyalomma marginatum, vector of Crimean-Congo haemorrhagic fever virus, into the United Kingdom by migratory birds. Ticks Tick Borne Dis, 3: 95–99.PubMedCrossRefGoogle Scholar
  38. Kebede S, Duales S, Yokouide A, and Alemu W. 2010. Trends of major disease outbreaks in the African region, 2003–2007. East Afr J Public Health, 7: 20–29.PubMedGoogle Scholar
  39. Keshtkar-Jahromi M, Kuhn J H, Christova I, Bradfute S B, Jahrling P B, and Bavari S. 2011. Crimean-Congo hemorrhagic fever: current and future prospects of vaccines and therapies. Antiviral Res, 90: 85–92.PubMedCrossRefGoogle Scholar
  40. Koksal I, Yilmaz G, Aksoy F, Aydin H, Yavuz I, Iskender S, Akcay K, Erensoy S, Caylan R, and Aydin K. 2010. The efficacy of ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Eastern Black Sea region in Turkey. J Clin Virol, 47: 65–68.PubMedCrossRefGoogle Scholar
  41. Kubar A, Haciomeroglu M, Ozkul A, Bagriacik U, Akinci E, Sener K, and Bodur H. 2011. Prompt administration of Crimean-Congo hemorrhagic fever (CCHF) virus hyperimmunoglobulin in patients diagnosed with CCHF and viral load monitorization by reverse transcriptase-PCR. Jpn J Infect Dis, 64: 439–443.PubMedGoogle Scholar
  42. Leblebicioglu H. 2010. Crimean-Congo haemorrhagic fever in Eurasia. Int J Antimicrob Agents, 36Suppl 1: S43–46.PubMedCrossRefGoogle Scholar
  43. Leblebicioglu H, Bodur H, Dokuzoguz B, Elaldi N, Guner R, Koksal I, Kurt H, and Senturk G C. 2012. Case management and supportive treatment for patients with crimean-congo hemorrhagic Fever. Vector Borne Zoonotic Dis, 12: 805–811.PubMedCrossRefGoogle Scholar
  44. Mardani M, and Keshtkar-Jahromi M. 2007. Crimean-Congo hemorrhagic fever. Arch Iran Med, 10: 204–214.PubMedGoogle Scholar
  45. Mardani M, Rahnavardi M, Rajaeinejad M, Naini K H, Chinikar S, Pourmalek F, Rostami M, and Shahri M H. 2007. Crimean-Congo hemorrhagic fever among health care workers in Iran: a seroprevalence study in two endemic regions. Am J Trop Med Hyg, 76: 443–445.PubMedGoogle Scholar
  46. Marty A M, Jahrling P B, and Geisbert T W. 2006. Viral hemorrhagic fevers. Clin Lab Med, 26: 345–386, viii.PubMedCrossRefGoogle Scholar
  47. Mofleh J, and Ahmad Z. 2012. Crimean-Congo haemorrhagic fever outbreak investigation in the Western Region of Afghanistan in 2008. East Mediterr Health J, 18: 522–526.PubMedGoogle Scholar
  48. Mourya D T, Yadav P D, Shete A M, Gurav Y K, Raut C G, Jadi R S, Pawar S D, Nichol S T, and Mishra A C. 2012. Detection, isolation and confirmation of Crimean-Congo hemorrhagic fever virus in human, ticks and animals in Ahmadabad, India, 2010–2011. PLoS Negl Trop Dis, 6: e1653.PubMedCrossRefGoogle Scholar
  49. Ozkurt Z, Kiki I, Erol S, Erdem F, Yilmaz N, Parlak M, Gundogdu M, and Tasyaran M A. 2006. Crimean-Congo hemorrhagic fever in Eastern Turkey: clinical features, risk factors and efficacy of ribavirin therapy. J Infect, 52: 207–215.PubMedCrossRefGoogle Scholar
  50. Ozturk B, Tutuncu E, Kuscu F, Gurbuz Y, Sencan I, and Tuzun H. 2012. Evaluation of factors predictive of the prognosis in Crimean-Congo hemorrhagic fever: new suggestions. Int J Infect Dis, 16: e89–93.PubMedCrossRefGoogle Scholar
  51. Papa A, Papadimitriou E, and Christova I. 2011. The Bulgarian vaccine Crimean-Congo haemorrhagic fever virus strain. Scand J Infect Dis, 43: 225–229.PubMedCrossRefGoogle Scholar
  52. Papa A, Bino S, Velo E, Harxhi A, Kota M, and Antoniadis A. 2006. Cytokine levels in Crimean-Congo hemorrhagic fever. J Clin Virol, 36: 272–276.PubMedCrossRefGoogle Scholar
  53. Purnak T, Selvi N A, and Altundag K. 2007. Global warming may increase the incidence and geographic range of Crimean-Congo Hemorrhagic Fever. Med Hypotheses, 68: 924–925.PubMedCrossRefGoogle Scholar
  54. Putilina N G, Azarian A R, Trusova I N, Mal’kov P M, Grishanova A P, Kovtunov A I, Shendo G L, Dzharkenov A F, Arshba T E, Larichev V F, and Butenko A M. 2011. Use of RT-PCR and enzyme immunoassays for the specific diagnosis of Crimean hemorrhagic fever. Vopr Virusol, 56: 34–38.PubMedGoogle Scholar
  55. Saijo M, Tang Q, Shimayi B, Han L, Zhang Y, Asiguma M, Tianshu D, Maeda A, Kurane I, and Morikawa S. 2004. Possible horizontal transmission of crimean-congo hemorrhagic Fever virus from a mother to her child. Jpn J Infect Dis, 57: 55–57.PubMedGoogle Scholar
  56. Saijo M, Tang Q, Shimayi B, Han L, Zhang Y, Asiguma M, Tianshu D, Maeda A, Kurane I, and Morikawa S. 2005. Antigen-capture enzyme-linked immunosorbent assay for the diagnosis of crimean-congo hemorrhagic fever using a novel monoclonal antibody. J Med Virol, 77: 83–88.PubMedCrossRefGoogle Scholar
  57. Sanchez-Seco M P, and Navarro J M. 2005. Infections due to Toscana virus, West Nile virus, and other arboviruses of interest in Europe. Enferm Infecc Microbiol Clin, 23: 560–568.PubMedCrossRefGoogle Scholar
  58. Sharifi-Mood B, Metanat M, Ghorbani-Vaghei A, Fayyaz-Jahani F, and Akrami E. 2009. The outcome of patients with Crimean-Congo hemorrhagic fever in Zahedan, southeast of Iran: a comparative study. Arch Iran Med, 12: 151–153.PubMedGoogle Scholar
  59. Shepherd A J, Swanepoel R, Leman P A, and Shepherd S P. 1986. Comparison of methods for isolation and titration of Crimean-Congo hemorrhagic fever virus. J Clin Microbiol, 24: 654–656.PubMedGoogle Scholar
  60. Soares-Weiser K, Thomas S, Thomson G, and Garner P. 2010. Ribavirin for Crimean-Congo hemorrhagic fever: systematic review and meta-analysis. BMC Infect Dis, 10: 207.PubMedCrossRefGoogle Scholar
  61. Tasdelen Fisgin N, Ergonul O, Doganci L, and Tulek N. 2009. The role of ribavirin in the therapy of Crimean-Congo hemorrhagic fever: early use is promising. Eur J Clin Microbiol Infect Dis, 28: 929–933.PubMedCrossRefGoogle Scholar
  62. Tekin S, Bursali A, Mutluay N, Keskin A, and Dundar E. 2012. Crimean-Congo hemorrhagic fever virus in various ixodid tick species from a highly endemic area. Vet Parasitol, 186: 546–552.PubMedCrossRefGoogle Scholar
  63. Tezer H, Sucakli I A, Sayli T R, Celikel E, Yakut I, Kara A, Tunc B, and Ergonul O. 2010. Crimean-Congo hemorrhagic fever in children. J Clin Virol, 48: 184–186.PubMedCrossRefGoogle Scholar
  64. Tignor G H, and Hanham C A. 1993. Ribavirin efficacy in an in vivo model of Crimean-Congo hemorrhagic fever virus (CCHF) infection. Antiviral Res, 22: 309–325.PubMedCrossRefGoogle Scholar
  65. Turkdogan K A, Zorlu A, Engin A, Guven F M, Polat M M, Turgut O O, and Yilmaz M B. 2012. C-type natriuretic peptide is associated with the severity of Crimean-Congo hemorrhagic fever. Int J Infect Dis, 16: e616–620.PubMedCrossRefGoogle Scholar
  66. Vanhomwegen J, Alves M J, Zupanc T A, Bino S, Chinikar S, Karlberg H, Korukluoglu G, Korva M, Mardani M, Mirazimi A, Mousavi M, Papa A, Saksida A, Sharifi-Mood B, Sidira P, Tsergouli K, Wolfel R, Zeller H, and Dubois P. 2012. Diagnostic assays for crimean-congo hemorrhagic fever. Emerg Infect Dis, 18: 1958–1965.PubMedCrossRefGoogle Scholar
  67. Vassilenko S M, Vassilev T L, Bozadjiev L G, Bineva I L, and Kazarov G Z. 1990. Specific intravenous immunoglobulin for Crimean-Congo haemorrhagic fever. Lancet, 335: 791–792.PubMedCrossRefGoogle Scholar
  68. Watts D M, Ussery M A, Nash D, and Peters C J. 1989. Inhibition of Crimean-Congo hemorrhagic fever viral infectivity yields in vitro by ribavirin. Am J Trop Med Hyg, 41: 581–585.PubMedGoogle Scholar
  69. Whitehouse C A. 2004. Crimean-Congo hemorrhagic fever. Antiviral Res, 64: 145–160.PubMedGoogle Scholar
  70. Xia H, Li P, Yang J, Pan L, Zhao J, Wang Z, Li Y, Zhou H, Dong Y, Guo S, Tang S, Zhang Z, Fan Z, Hu Z, Kou Z, and Li T. 2011. Epidemiological survey of Crimean-Congo hemorrhagic fever virus in Yunnan, China, 2008. Int J Infect Dis, 15: e459–463.PubMedCrossRefGoogle Scholar
  71. Yen Y C, Kong L X, Lee L, Zhang Y Q, Li F, Cai B J, and Gao S Y. 1985. Characteristics of Crimean-Congo hemorrhagic fever virus (Xinjiang strain) in China. Am J Trop Med Hyg, 34: 1179–1182.PubMedGoogle Scholar
  72. Zeller H. 2007. Laboratory Diagnosis of Crimean-Congo Hemorrhagic Fever, p. 233–243. In Ergonul O and Whitehouse C A (ed.), Crimean-Congo Hemorrhagic Fever: A Global Perspective. Springer, Dordrecht.CrossRefGoogle Scholar

Copyright information

© Wuhan Institute of Virology, CAS and Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Department of Infectious Diseases and Clinical MicrobiologyAdnan Menderes University Medical FacultyAydinTurkey

Personalised recommendations